Molecular Therapy Oncolytics最新文献

{"title":"miR-146a: Overcoming coldness in ovarian cancer","authors":"Yanqi Ye, Nanhai G. Chen","doi":"10.1016/j.omto.2023.100753","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100753","url":null,"abstract":"Abstract not available","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"33 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New advances in cancer therapy targeting TGF-β signaling pathways","authors":"Minyue Shou, Hanyu Zhou, Ling Ma","doi":"10.1016/j.omto.2023.100755","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100755","url":null,"abstract":"Abstract not available","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"191 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting mesothelin in cancer","authors":"Cem Elbi","doi":"10.1016/j.omto.2023.100756","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100756","url":null,"abstract":"Abstract not available","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"14 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thank you to our 2023 reviewers","authors":"","doi":"10.1016/j.omto.2023.100757","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100757","url":null,"abstract":"Abstract not available","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"232 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaining insights into virotherapy with canine models","authors":"Jacob L. Léger, Lee-Hwa Tai","doi":"10.1016/j.omto.2023.100754","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100754","url":null,"abstract":"Abstract not available","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"232 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role and Application of Vesicles in Triple-negative Breast Cancer: Opportunities and Challenges","authors":"Ya-Nan Wei, Chun-Yan Yan, Meng-Lu Zhao, Xi-He Zhao","doi":"10.1016/j.omto.2023.100752","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100752","url":null,"abstract":"<p>EVs (Extracellular vesicles) carry DNA, RNA, protein and other substances involved in intercellular crosstalk and can be used for the targeted delivery of drugs. TNBC (Triple-negative breast cancer) is rich in recurrent and metastatic disease and lacks therapeutic targets. Studies have proved the role of EVs in the different stages of the genesis and development of TNBC. Cancer cells actively secrete various biomolecules, which play a significant part establishing the TME (tumor microenvironment) via EVs. In this article, we describe the roles of EVs in tumor immune microenvironment, metabolic microenvironment and vascular remodeling, and summarize the application of EVs for objective delivery of chemotherapeutic drugs, immune antigens and cancer vaccine adjuvants. EVs-based therapy may represent the next-generation tool for targeted drug delivery for the cure of a variety of diseases lacking effective drug treatment.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"1997 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","authors":"Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark Leick, Estelle V. Cervantes, Tayyebb Ghafoor, Kayla Reid, Kristen Spitler, Bin Yu, Brian C. Betts, Jose A. Guevara-Patino, Marcela V. Maus, Marco L. Davila","doi":"10.1016/j.omto.2023.100751","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100751","url":null,"abstract":"<p>CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts and other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen receptor T cell therapies that target both CD33 and CD123. To overcome this limitation, we developed bispecific human CD33/CD123 chimeric antigen receptor (CAR) T cells with an “AND” logic gate. We produced novel CD33 and CD123 scFvs from monoclonal antibodies that bound CD33 and CD123 and activated T cells. Screening of CD33 and CD123 CAR T cells for cytotoxicity, cytokine production, and proliferation was performed, and we selected scFvs for CD33/CD123 bispecific CARs. The bispecific CARs split 4-1BB co-stimulation on one scFv and CD3ζ on the other. <em>In vitro</em> testing of cytokine secretion and cytotoxicity resulted in selecting bispecific CAR 1 construct for <em>in vivo</em> analysis. The CD33/CD123 bispecific CAR T cells were able to control acute myeloid leukemia (AML) in a xenograft AML mouse model similar to monospecific CD33 and CD123 CAR T cells while showing no on-target off-tumor effects. Based on our findings, human CD33/CD123 bispecific CAR T cells are a promising cell-based approach to prevent AML and support clinical investigation.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"44 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138541951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Therapy Oncology: What’s in a name?","authors":"Timothy P. Cripe","doi":"10.1016/j.omto.2023.100739","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100739","url":null,"abstract":"In 2014, the American Society of Cell and Gene Therapy (ASGCT) launched a sibling journal to Molecular Therapy (MT), Molecular Therapy - Oncolytics (MTO), to accommodate the blossoming field of cancer biologics and publish studies that involved “engineering cells, viruses, or other microorganisms to combat cancer.”1Fong Y. MTO: a new journal for a maturing field.Mol. Ther. Oncolytics. 2014; 114001https://doi.org/10.1038/mto.2014.1Abstract Full Text Full Text PDF Scopus (0) Google Scholar Similar to the other MT sibling journals, MTO was intended to be an outlet for cancer therapy papers that deserved to be published but were more specialized and needed a more targeted audience. Their timing was right on, as it was concurrent with the first FDA approval of an anti-PD-1 antibody, and the following year, we saw the first FDA approval of an oncolytic virus as a cancer therapy.2First Oncolytic Viral Therapy for Melanoma.Cancer Discov. 2016; 6: 6https://doi.org/10.1158/2159-8290.CD-NB2015-158Crossref PubMed Scopus (34) Google Scholar Another 2 years thereafter, the FDA approved an engineered cell therapy for leukemia.3Bach P.B. Giralt S.A. Saltz L.B. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.JAMA. 2017; 318: 1861-1862https://doi.org/10.1001/jama.2017.15218Crossref PubMed Scopus (123) Google Scholar Since then, checkpoint inhibitors have flourished, and cell therapies have exploded,4Mitra A. Barua A. Huang L. Ganguly S. Feng Q. He B. From bench to bedside: the history and progress of CAR T cell therapy.Front. Immunol. 2023; 141188049https://doi.org/10.3389/fimmu.2023.1188049Crossref Scopus (3) Google Scholar with six FDA-approved products so far and global markets estimated to reach $50 billion by 2030. Sadly, there has not yet been another oncolytic virus on the US market, though a few have received conditional approvals in other countries.5Zamecnik A. Immunotherapy insights: Oncolytic viruses struggle to find a spot in a crowded field.Pharm. Technol. 2023; https://www.pharmaceutical-technology.com/features/immunotherapy-insights-oncolytic-viruses-struggle-to-find-a-spot-in-a-crowded-field/Google Scholar Encouragingly, there have been promising clinical data reported in small studies in certain settings,6Desjardins A. Gromeier M. Herndon J.E. Beaubier N. Bolognesi D.P. Friedman A.H. Friedman H.S. McSherry F. Muscat A.M. Nair S. et al.Recurrent Glioblastoma Treated with Recombinant Poliovirus.N. Engl. J. Med. 2018; 379: 150-161https://doi.org/10.1056/NEJMoa1716435Crossref PubMed Scopus (486) Google Scholar,7Friedman G.K. Johnston J.M. Bag A.K. Bernstock J.D. Li R. Aban I. Kachurak K. Nan L. Kang K.-D. Totsch S. et al.Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.N. Engl. J. Med. 2021; 384: 1613-1622https://doi.org/10.1056/NEJMoa2024947Crossref PubMed Scopus (144) Google Scholar,8Gállego Pérez-Larraya J. Garcia-Moure M. Labiano S. Patiño-García A. Dobbs J. Gonzalez-Huarriz M. Zalacain M","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"1 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.","authors":"Charlotte O’Brien Gore, Amy Billman, Suchete Hunjan, Jayne Colebrook, Desmond Choy, Wilson Li, Jack Haynes, Jennifer Wade, Emily Hobern, Louisa McDonald, Sophie Papa, Martijn Brugman, Shahram Kordasti, Claudia Montiel-Equihua","doi":"10.1016/j.omto.2023.100749","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100749","url":null,"abstract":"","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"2014 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer","authors":"Jessica A. Minott, Jacob P. van Vloten, Jake G.E. Yates, Lisa A. Santry, Kathy Matuszewska, Madison Pereira, Melanie M. Goens, Alicia Viloria-Petit, Geoffrey A. Wood, Khalil Karimi, James J. Petrik, Byram W. Bridle, Sarah K. Wootton","doi":"10.1016/j.omto.2023.100748","DOIUrl":"https://doi.org/10.1016/j.omto.2023.100748","url":null,"abstract":"","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"6 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}